These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30829606)

  • 1. [A COMPARATIVE ANALYSIS OF THE DISPERSION QUALITY OF NASAL SPRAYS OXYMETAZOLINE].
    Yankova V; Udyanskaya I; Slonskaya T; Plakhotnaya O; Gogokhia T
    Georgian Med News; 2019 Jan; (286):136-140. PubMed ID: 30829606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging.
    Pritchard S; Glover M; Guthrie G; Brum J; Ramsey D; Kappler G; Thomas P; Stuart S; Hull D; Gowland P
    Pulm Pharmacol Ther; 2014 Feb; 27(1):121-6. PubMed ID: 23988443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers.
    Cacek AT; Gobburu JV; Gopalakrishnan M
    J Clin Pharmacol; 2017 Feb; 57(2):247-254. PubMed ID: 27436060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of the dispersion quality of oxymetazoline nasal sprays.
    Gobyzov OA; Ryabov MN; Yankova VG; Gribanova SV; Slonskaya TK; Udyanskaya IL; Zhukova AA; Grigoryeva VY
    J Adv Pharm Technol Res; 2022; 13(1):30-37. PubMed ID: 35223438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Effect of Sinex® (0.05% Oxymetazoline) Nasal Spray on Reduction of Nasal Congestion Using Computational Fluid Dynamics.
    Kishore A; Blake L; Wang C; Ba S; Gross G
    J Biomech Eng; 2015 Aug; 137(8):081011. PubMed ID: 26065640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours.
    Druce HM; Ramsey DL; Karnati S; Carr AN
    Rhinology; 2018 Dec; 56(4):343-350. PubMed ID: 29785414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new nasal decongestant, A-57219: a comparison with oxymetazoline.
    DeBernardis JF; Winn M; Kerkman DJ; Kyncl JJ; Buckner S; Horrom B
    J Pharm Pharmacol; 1987 Sep; 39(9):760-3. PubMed ID: 2445950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays.
    Graf P; Hallén H
    Laryngoscope; 1996 May; 106(5 Pt 1):605-9. PubMed ID: 8628089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray.
    Rajpal S; Morris LA; Akkus NI
    Rev Port Cardiol; 2014 Jan; 33(1):51.e1-4. PubMed ID: 24405558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use.
    Cartabuke R; Tobias JD; Jatana KR;
    Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34607935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline.
    Vaidyanathan S; Williamson P; Lipworth B
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):77-80. PubMed ID: 22289724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oxymetazoline nasal spray on the nasal cycle assessed by long-term rhinoflowmetry.
    Braun T; Rich M; Berghaus A; Kramer MF
    Rhinology; 2012 Dec; 50(4):370-5. PubMed ID: 23181250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute coronary syndrome after nasal spray of oxymetazoline.
    Montastruc F; Montastruc G; Taudou MJ; Olivier-Abbal P; Montastruc JL; Bondon-Guitton E
    Chest; 2014 Dec; 146(6):e214-e215. PubMed ID: 25451367
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of topical nasal decongestants on histology of nasal respiratory mucosa in rabbits.
    Suh SH; Chon KM; Min YG; Jeong CH; Hong SH
    Acta Otolaryngol; 1995 Sep; 115(5):664-71. PubMed ID: 8928640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended use of topical nasal decongestants.
    Yoo JK; Seikaly H; Calhoun KH
    Laryngoscope; 1997 Jan; 107(1):40-3. PubMed ID: 9001263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers.
    Hallén H; Graf P
    Clin Exp Allergy; 1995 May; 25(5):401-5. PubMed ID: 7553242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa.
    Ferguson BJ; Paramaesvaran S; Rubinstein E
    Otolaryngol Head Neck Surg; 2001 Sep; 125(3):253-60. PubMed ID: 11555762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].
    Teng Y; Zhang X; Xu G; Cai Q; Xu J
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Sep; 19(18):824-6. PubMed ID: 16375111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method.
    Kundoor V; Dalby RN
    Pharm Res; 2010 Jan; 27(1):30-6. PubMed ID: 19902337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.